BIO Submits Brief of Amicus Curiae in Sandoz Inc. v. Amgen Manufacutring Inc. and Amgen Manufacturing Ltd v. Sandoz Inc. (Supreme Court of the United States)

The Biotechnology Innovation Organization
(“BIO”) is the principal trade association representing
the biotechnology industry in all fifty states and
abroad. BIO has more than 1,000 members, including
businesses, biotechnology centers, and academic
institutions.

BIO members undertake research and
development of biotechnological health care,
agricultural, environmental, and industrial products,
including innovative life-saving drugs as well as
biosimilars. BIO’s members range from Fortune 500
companies to research universities and small start-up
companies. The majority of BIO’s corporate members
are development-stage companies that have yet to
bring their first commercial product to market.

As one of the leading proponents for the
creation of a biosimilar approval pathway that also
maintained incentives for continued innovation, BIO has a strong interest in the proper implementation of
this statutory scheme by the courts.